Search

Your search keyword '"Mosenzon, Ofri"' showing total 708 results
Start Over Author "Mosenzon, Ofri"
708 results on '"Mosenzon, Ofri"'

103. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Author

Udell, Jacob A., Bhatt, Deepak L., Braunwald, Eugene, Cavender, Matthew A., Mosenzon, Ofri, Steg, Ph. Gabriel, Davidson, Jaime A., Nicolau, Jose C., Corbalan, Ramon, Hirshberg, Boaz, Frederich, Robert, Im, KyungAh, Umez-Eronini, Amarachi A., He, Ping, McGuire, Darren K., Leiter, Lawrence A., Raz, Itamar, and Scirica, Benjamin M.

Published
2015
Full Text
View/download PDF

104. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

Author

Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D., Schechter, Meir, Goodrich, Erica L., Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A., Zelniker, Thomas A., Langkilde, Anna Maria, Gause-Nilsson, Ingrid A.M., Fredriksson, Martin, Johansson, Peter A., Wilding, John P.H., McGuire, Darren K., Bhatt, Deepak L., Leiter, Lawrence A., Cahn, Avivit, Dwyer, Jamie P., and Heerspink, Hiddo J.L.

Subjects
*MYOCARDIAL infarction complications, *GLOMERULAR filtration rate, *BENZENE, *RESEARCH, *SODIUM, *RESEARCH methodology, *GLYCOSIDES, *EVALUATION research, *TYPE 2 diabetes, *COMPARATIVE studies, *RANDOMIZED controlled trials, *GLUCOSE, *DIABETIC nephropathies, *DISEASE complications
Abstract

Objective: In patients with moderate to severe albuminuric kidney disease, sodium-glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function decline in patients with type 2 diabetes (T2D), focusing on populations with low kidney risk.Research Design and Methods: In the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial, patients with T2D at high cardiovascular risk were randomly assigned to dapagliflozin versus placebo. Outcomes were analyzed by treatment arms, overall, and by Kidney Disease: Improving Global Outcomes (KDIGO) risk categories. The prespecified kidney-specific composite outcome was a sustained decline ≥40% in the estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m2, end-stage kidney disease, and kidney-related death. Other outcomes included incidence of categorical eGFR decline of different thresholds and chronic (6 month to 4 year) or total (baseline to 4 year) eGFR slopes.Results: Most participants were in the low-moderate KDIGO risk categories (n = 15,201 [90.3%]). The hazard for the kidney-specific composite outcome was lower with dapagliflozin across all KDIGO risk categories (P-interaction = 0.97), including those at low risk (hazard ratio [HR] 0.54, 95% CI 0.38-0.77). Risks for categorical eGFR reductions (≥57% [in those with baseline eGFR ≥60 mL/min/1.73 m2], ≥50%, ≥40%, and ≥30%) were lower with dapagliflozin (HRs 0.52, 0.57, 0.55, and 0.70, respectively; P < 0.05). Slopes of eGFR decline favored dapagliflozin across KDIGO risk categories, including the low KDIGO risk (between-arm differences of 0.87 [chronic] and 0.55 [total] mL/min/1.73 m2/year; P < 0.0001).Conclusions: Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

105. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial.

Author

Oyama, Kazuma, Raz, Itamar, Cahn, Avivit, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John P H, Park, Kyong Soo, Goudev, Assen, Diaz, Rafael, Špinar, Jindřich, Gause-Nilsson, Ingrid A M, Mosenzon, Ofri, Sabatine, Marc S, and Wiviott, Stephen D

Subjects
TYPE 2 diabetes, SODIUM-glucose cotransporter 2 inhibitors, DAPAGLIFLOZIN, ATRIAL flutter, DISEASE risk factors
Abstract

Aims  We investigated the associations between obesity, cardiorenal events, and benefits of dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results  DECLARE–TIMI 58 randomized patients with T2DM and either atherosclerotic cardiovascular (CV) disease or multiple risk factors to dapagliflozin vs. placebo. Patients were stratified by body mass index (BMI, kg/m2): normal (18.5 to <25), overweight (25 to <30), moderately obese (30 to <35), severely obese (35 to <40), and very-severely obese (≥40). Outcomes analysed were CV death, hospitalization for heart failure (HHF), renal-specific composite outcome, and atrial fibrillation or flutter (AF/AFL). Of 17 134 patients, 9.0% had a normal BMI, 31.5% were overweight, 32.4% were moderately, 17.2% severely, and 9.8% were very-severely obese. Higher BMI was associated with a higher adjusted risk of HHF and AF/AFL (hazard ratio 1.30 and 1.28, respectively, per 5 kg/m2; P  < 0.001 for all). Dapagliflozin reduced body weight by similar relative amounts consistently across BMI categories (percent difference: −1.9 to −2.4%). Although relative risk reductions in CV and renal-specific composite outcomes with dapagliflozin did not significantly differ across the range of BMI (P for interaction ≥0.20 for all outcomes), obese patients (BMI ≥ 30 kg/m2) tended to derive greater absolute risk reduction in HHF and AF/AFL (P for interaction 0.02 and 0.09, respectively) than non-obese patients. Conclusions  In DECLARE–TIMI 58, patients with T2DM and higher BMI were more likely to have HHF and AF/AFL. Whereas relative risk reductions in CV and renal outcomes with dapagliflozin were generally consistent across the range of BMI, absolute risk reduction in obesity-related outcomes including HHF and AF/AFL tended to be larger in obese patients with T2DM. Clinical trial registration URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01730534. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

109. Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents

Author

Shapiro, Michael, primary, Arbel, Chen, additional, Zucker, Inbar, additional, Balmor, Gingy Ronen, additional, Lutski, Miri, additional, Derazne, Estela, additional, Beer, Zivan, additional, Pinhas-Hamiel, Orit, additional, Mosenzon, Ofri, additional, Tzur, Dorit, additional, Afek, Arnon, additional, Tirosh, Amir, additional, Cukierman-Yaffe, Tali, additional, Gerstein, Hertzel C, additional, Rosenberg, Vered, additional, Chodick, Gabriel, additional, Raz, Itamar, additional, and Twig, Gilad, additional

Published
2021
Full Text
View/download PDF

111. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes

Author

Zelniker, Thomas A., primary, Raz, Itamar, additional, Mosenzon, Ofri, additional, Dwyer, Jamie P., additional, Heerspink, Hiddo H. J. L., additional, Cahn, Avivit, additional, Goodrich, Erica L., additional, Im, Kyungah, additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P. H., additional, Gause-Nilsson, Ingrid, additional, Langkilde, Anna Maria, additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2021
Full Text
View/download PDF

112. 990-P: Use of Glucose-Lowering Agents According to Cardiovascular Risk Factors in People with T2D and with or without CVD in the CAPTURE Study

Author

DIEUZEIDE, GUILLERMO, primary, ALGUWAIHES, ABDULLAH M., additional, LEON, JOSE LUIS A., additional, BAYRAM, FAHRI, additional, DARMON, PATRICE, additional, DAVIS, TIMOTHY, additional, ERIKSEN, KIRSTEN T., additional, HONG, TIANPEI, additional, JENSEN, THOMAS J., additional, LENGYEL, CSABA, additional, MOSENZON, OFRI, additional, RUSSO, GIUSEPPINA T., additional, SHIRABE, SHINICHIRO, additional, URBANCOVA, KATERINA, additional, VENCIO, SERGIO, additional, and YADAV, GOURAV, additional

Published
2021
Full Text
View/download PDF

113. Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History

Author

Garvey, W. Timothy, primary, Hesse, Dan, additional, Koroleva, Anna, additional, Kushner, Robert F., additional, Lim, Soo, additional, Lingvay, Ildiko, additional, Mosenzon, Ofri, additional, Wallenstein, Signe O., additional, Wadden, Thomas A., additional, and Le Roux, Carel W., additional

Published
2021
Full Text
View/download PDF

115. 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58

Author

CAHN, AVIVIT, primary, WIVIOTT, STEPHEN D., additional, MOSENZON, OFRI, additional, MURPHY, SABINA, additional, GOODRICH, ERICA L., additional, BHATT, DEEPAK L., additional, LEITER, LAWRENCE A., additional, MCGUIRE, DARREN K., additional, WILDING, JOHN, additional, GAUSE-NILSSON, INGRID A., additional, LANGKILDE, ANNA MARIA, additional, SABATINE, MARC S., additional, and RAZ, ITAMAR, additional

Published
2021
Full Text
View/download PDF

116. 974-P: Associations between Patient Characteristics and Cardiovascular Disease: A Post-hoc Analysis from the CAPTURE Study

Author

ALGUWAIHES, ABDULLAH M., primary, LEON, JOSE LUIS A., additional, BAYRAM, FAHRI, additional, DARMON, PATRICE, additional, DAVIS, TIMOTHY, additional, DIEUZEIDE, GUILLERMO, additional, ERIKSEN, KIRSTEN T., additional, HONG, TIANPEI, additional, JENSEN, THOMAS J., additional, LENGYEL, CSABA, additional, MOSENZON, OFRI, additional, RUSSO, GIUSEPPINA T., additional, SHIRABE, SHINICHIRO, additional, URBANCOVA, KATERINA, additional, VENCIO, SERGIO, additional, and YADAV, GOURAV, additional

Published
2021
Full Text
View/download PDF

117. Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood

Author

Bardugo, Aya, primary, Derazne, Estela, additional, Zucker, Inbar, additional, Bendor, Cole D, additional, Puris, Gal, additional, Lutski, Miri, additional, Pinhas-Hamiel, Orit, additional, Cukierman-Yaffe, Tali, additional, Mosenzon, Ofri, additional, Schechter, Meir, additional, Tzur, Dorit, additional, Afek, Arnon, additional, Tirosh, Amir, additional, Gerstein, Hertzel C, additional, Raz, Itamar, additional, and Twig, Gilad, additional

Published
2021
Full Text
View/download PDF

120. MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58

Author

Berg, David, primary, Wiviott, Stephen, additional, Goodrich, Erica, additional, Murphy, Sabina, additional, Mosenzon, Ofri, additional, Bhatt, Deepak, additional, Cahn, Avivit, additional, Leiter, Lawrence, additional, McGuire, Darren, additional, Wilding, John, additional, Gause-Nilsson, Ingrid, additional, Hammarstedt, Ann, additional, Karlsson, Cecilia, additional, Johansson, Peter, additional, Langkilde, Anna-Maria, additional, Raz, Itamar, additional, and Sabatine, Marc, additional

Published
2021
Full Text
View/download PDF

123. Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Author

Rubino, Domenica M, primary, Abrahamsson, Niclas, additional, Davies, Melanie, additional, Hesse, Dan, additional, Greenway, Frank L, additional, Jensen, Camilla, additional, Lingvay, Ildiko, additional, Mosenzon, Ofri, additional, Rosenstock, Julio, additional, Rubio, Miguel A, additional, Rudofsky, Gottfried, additional, Tadayon, Sayeh, additional, Wadden, Thomas A, additional, and Dicker, Dror, additional

Published
2021
Full Text
View/download PDF

124. Additional file 1 of CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Author

Mosenzon, Ofri, Alguwaihes, Abdullah, Leon, Jose Luis Arenas, Bayram, Fahri, Darmon, Patrice, Davis, Timothy M. E., Dieuzeide, Guillermo, Eriksen, Kirsten T., Hong, Tianpei, Kaltoft, Margit S., Lengyel, Csaba, Rhee, Nicolai A., Russo, Giuseppina T., Shirabe, Shinichiro, Urbancova, Katerina, and Vencio, Sergio

Abstract

Additional file 1. Additional methods, data and analyses and full list of CAPTURE study investigators/collaborators.

Published
2021
Full Text
View/download PDF

125. Asthma & Type 2 Diabetes - Supplementary Appendix.pdf

Author

Shapiro, Michael, Arbel, Chen, Zucker, Inbar, Balmor, Gingy Ronen, Lutski, Miri, Derazne, Estela, Beer, Zivan, Pinhas-Hamiel, Orit, Mosenzon, Ofri, Tzur, Durit, Afek, Arnon, Tirosh, Amir, Cukierman-Yaffe, Tali, Gerstein, Hertzel C, Rozenberg, Vered, Chodik, Gabriel, Raz, Itamar, and Twig, Gilad

Abstract

Supplementary Appendix for manuscript titled: "Asthma in Youth and Early-Onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents"

Published
2021
Full Text
View/download PDF

126. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial

Author

Rubino, Domenica, Abrahamsson, Niclas, Davies, Melanie, Hesse, Dan, Greenway, Frank L., Jensen, Camilla, Lingvay, Ildiko, Mosenzon, Ofri, Rosenstock, Julio, Rubio, Miguel A., Rudofsky, Gottfried, Tadayon, Sayeh, Wadden, Thomas A., Dicker, Dror, Rubino, Domenica, Abrahamsson, Niclas, Davies, Melanie, Hesse, Dan, Greenway, Frank L., Jensen, Camilla, Lingvay, Ildiko, Mosenzon, Ofri, Rosenstock, Julio, Rubio, Miguel A., Rudofsky, Gottfried, Tadayon, Sayeh, Wadden, Thomas A., and Dicker, Dror

Abstract

IMPORTANCE The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown. OBJECTIVE To compare continued once-weekly treatment with subcutaneous semaglutide, 2.4 mg, with switch to placebo for weight maintenance (both with lifestyle intervention) in adults with overweight or obesity after a 20-week run-in with subcutaneous semaglutide titrated to 2.4 mg weekly. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites in 10 countries from June 2018 to March 2020 in adults with body mass index of at least 30 (or 7 , -27 with >1 weight-related comorbidity) and without diabetes. INTERVENTIONS A total of 902 participants received once-weekly subcutaneous semaglutide during run-in. After 20 weeks (16 weeks of dose escalation; 4 weeks of maintenance dose), 803 participants (89.0%) who reached the 2.4-mg/wk semaglutide maintenance dose were randomized (2:1) to 48 weeks of continued subcutaneous semaglutide (n = 535) or switched to placebo (n = 268), plus lifestyle intervention in both groups. MAIN OUTCOMES AND MEASURES The primary end point was percent change in body weight from week 20 to week 68; confirmatory secondary end points were changes in waist circumference, systolic blood pressure, and physical functioning (assessed using the Short Form 36 Version 2 Health Survey, Acute Version [SF-36]). RESULTS Among 803 study participants who completed the 20-week run-in period (with a mean weight loss of 10.6%) and were randomized (mean age, 46 [SD, 12] years; 634 [79%] women; mean body weight, 107.2 kg [SD, 22.7 kg]), 787 participants (98.0%) completed the trial and 741(92.3%) completed treatment. With continued semaglutide, mean body weight change from week 20 to week 68 was -7.9% vs +6.9% with the switch to placebo (difference, -14.8 [95% CI, -16.0 to -13.5] percentage points; P < .001).

Published
2021
Full Text
View/download PDF

127. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes:A Post Hoc Analysis of the LEADER Trial

Author

Persson, Frederik, Bain, Stephen C, Mosenzon, Ofri, Heerspink, Hiddo J L, Mann, Johannes F E, Pratley, Richard, Raz, Itamar, Idorn, Thomas, Rasmussen, Søren, von Scholten, Bernt Johan, Rossing, Peter, Persson, Frederik, Bain, Stephen C, Mosenzon, Ofri, Heerspink, Hiddo J L, Mann, Johannes F E, Pratley, Richard, Raz, Itamar, Idorn, Thomas, Rasmussen, Søren, von Scholten, Bernt Johan, and Rossing, Peter

Abstract

OBJECTIVE: A post hoc analysis to investigate the association between 1-year changes in albuminuria and subsequent risk of cardiovascular and renal events.RESEARCH DESIGN AND METHODS: LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk. We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with >30% reduction (n = 2,928), 30-0% reduction (n = 1,218), or any increase in UACR (n = 4,124), irrespective of treatment. Using Cox regression, risks of major adverse cardiovascular events (MACE) and a composite nephropathy outcome (from 1 year to end of trial in subgroups by baseline UACR [<30 mg/g, 30-300 mg/g, or ≥300 mg/g]) were assessed. The analysis was adjusted for treatment allocation alone as a fixed factor and for baseline variables associated with cardiovascular and renal outcomes.RESULTS: For MACE, hazard ratios (HRs) for those with >30% and 30-0% UACR reduction were 0.82 (95% CI 0.71, 0.94; P = 0.006) and 0.99 (0.82, 1.19; P = 0.912), respectively, compared with any increase in UACR (reference). For the composite nephropathy outcome, respective HRs were 0.67 (0.49, 0.93; P = 0.02) and 0.97 (0.66, 1.43; P = 0.881). Results were independent of baseline UACR and consistent in both treatment groups. After adjustment, HRs were significant and consistent in >30% reduction subgroups with baseline micro- or macroalbuminuria.CONCLUSIONS: A reduction in albuminuria during the 1st year was associated with fewer cardiovascular and renal outcomes, independent of treatment. Albuminuria monitoring remains an important part of diabetes care, with great unused potential.

Published
2021

129. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Author

von Herrath, Matthias, primary, Bain, Stephen C, additional, Bode, Bruce, additional, Clausen, Jesper Ole, additional, Coppieters, Ken, additional, Gaysina, Leylya, additional, Gumprecht, Janusz, additional, Hansen, Troels Krarup, additional, Mathieu, Chantal, additional, Morales, Cristobal, additional, Mosenzon, Ofri, additional, Segel, Stine, additional, Tsoukas, George, additional, Pieber, Thomas R, additional, Ludvik, Bernhard, additional, Prager, Rudolf, additional, Paulweber, Bernhard, additional, Ebenbichler, Christoph F, additional, Keymeulen, B, additional, De Block, C, additional, Grossman, Loren, additional, Houlden, Robyn, additional, Perron, Patrice, additional, Ransom, Thomas, additional, Senior, Peter, additional, Weisnagel, S. John, additional, Woo, Vincent, additional, Dumas, Richard, additional, Thompson, David, additional, Vilsbøll, Tina, additional, Gram, Jeppe, additional, Juhl, Claus Bogh, additional, Hukkanen, Janne, additional, Lahtela, Jorma, additional, Niskanen, Leo, additional, O'Shea, Donal, additional, O'Brien, Timothy, additional, Sreenan, Seamus, additional, Wainstein, Julio, additional, Phillip, Moshe, additional, Knobler, Hilla, additional, Dotta, Francesco, additional, Piatti, Pier Marco, additional, Roberto, Trevisan, additional, Gnasso, Agostino, additional, Gulseth, Hanne, additional, Cooper, John, additional, Pankowska, Ewa, additional, Lukaszewicz, Monika, additional, Wolnik, Bogumił, additional, Manita, Isabel, additional, Marques, Olinda, additional, Roque, Cristina, additional, Príncipe, Rosa Maria, additional, Neves, Celestino, additional, Heitor, Susana, additional, Ruyatkina, L, additional, Dvoryashina, Irina, additional, Vagapova, Gulnar, additional, Belousova, Lidiya, additional, Sergeeva-Kondrachenko, Marina, additional, Peskov, Andrey, additional, Frolova, Elena, additional, Golovach, Albina, additional, Kunitsyna, Marina, additional, Krasnopeeva (Kabachkova), Natalia, additional, Ipatko, Irina, additional, De la Cuesta, Carmen, additional, Tinahones, Francisco José, additional, Rigla, Mercedes, additional, Merino, Juan Francisco, additional, Gómez, Luis Alberto, additional, Fernández, Mercè, additional, Simó, Rafael, additional, Rydén, Mikael, additional, Jendle, Johan, additional, Filipsson, Karin, additional, Eliasson, Björn, additional, Mankovsky, Borys, additional, Lymar, Iurii, additional, Sokolova, Liubov, additional, Myshanych, Galyna, additional, Zlova, Tetiana, additional, Vlasenko, Maryna, additional, Kuskalo -, Petro, additional, Courtney, Hamish, additional, Dayan, Colin, additional, English, Patrick, additional, Heller, Simon, additional, Johnson, Andrew B, additional, Nair, Sunil, additional, Leslie, R. D, additional, Narendran, P, additional, Oliver, Nick, additional, Ramtoola, Shenaz, additional, Shaw, Jim, additional, Viljoen -, Adie, additional, Al-Karadsheh, Amer, additional, Dostou, Jean Marie, additional, Gangi, Sumana, additional, Gottlieb, Peter, additional, Jerkins, Terri, additional, Magnotti, Michael, additional, Marks, Jennifer, additional, Nakhle, Samer, additional, Bonabi, Gholamreza, additional, Myers, Lyle, additional, Pratley, Richard, additional, Hagopian, William, additional, Pettus, Jeremy, additional, von Scholten, Bernt Johan, additional, Wesley, Johnna D, additional, and Kreiner, Frederik F, additional

Published
2021
Full Text
View/download PDF

130. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Author

Cahn, Avivit, primary, Raz, Itamar, primary, Leiter, Lawrence A., primary, Mosenzon, Ofri, primary, Murphy, Sabina A., primary, Goodrich, Erica L., primary, Yanuv, Ilan, primary, Rozenberg, Aliza, primary, Bhatt, Deepak L., primary, McGuire, Darren K., primary, Wilding, John P.H., primary, Gause-Nilsson, Ingrid A. M., primary, Langkilde, Anna Maria, primary, Sabatine, Marc S., primary, and Wiviott, Stephen D., primary

Published
2021
Full Text
View/download PDF

131. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease

Author

Marston, Nicholas A., primary, Melloni, Giorgio E.M., additional, Gurmu, Yared, additional, Bonaca, Marc P., additional, Kamanu, Frederick K., additional, Roselli, Carolina, additional, Lee, Christina, additional, Cavallari, Ilaria, additional, Giugliano, Robert P., additional, Scirica, Benjamin M., additional, Bhatt, Deepak L., additional, Steg, Philippe Gabriel, additional, Cohen, Marc, additional, Storey, Robert F., additional, Keech, Anthony C., additional, Raz, Itamar, additional, Mosenzon, Ofri, additional, Braunwald, Eugene, additional, Lubitz, Steven A., additional, Ellinor, Patrick T., additional, Sabatine, Marc S., additional, and Ruff, Christian T., additional

Published
2021
Full Text
View/download PDF

132. Cardiovascular and renal outcomes by baseline albuminuria status and renal function:Results from the LEADER randomized trial

Author

Mosenzon, Ofri, Bain, Stephen C., Heerspink, Hiddo J.L., Idorn, Thomas, Mann, Johannes F.E., Persson, Frederik, Pratley, Richard E., Rasmussen, Søren, Rossing, Peter, von Scholten, Bernt Johan, Raz, Itamar, Mosenzon, Ofri, Bain, Stephen C., Heerspink, Hiddo J.L., Idorn, Thomas, Mann, Johannes F.E., Persson, Frederik, Pratley, Richard E., Rasmussen, Søren, Rossing, Peter, von Scholten, Bernt Johan, and Raz, Itamar

Abstract

Aim: To assess cardiorenal outcomes by baseline urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in the contemporary LEADER cohort. Materials and methods: LEADER was a multinational, double-blind trial. Patients with type 2 diabetes and high cardiovascular (CV) risk were randomized 1:1 to the glucagon-like peptide-1 analogue liraglutide (≤1.8 mg daily; n = 4668) or placebo (n = 4672) plus standard care and followed for 3.5 to 5 years. Primary composite outcomes were time to first non-fatal myocardial infarction, non-fatal stroke or CV death. Post hoc Cox regression analyses of outcomes by baseline UACR and eGFR subgroups were conducted with adjustment for baseline variables. Results: In the LEADER population, 1598 (17.5%), 2917 (31.9%), 1200 (13.1%), 1611 (17.6%), 845 (9.2%) and 966 (10.6%) had UACR = 0, >0 to <15, 15 to <30, 30 to <100, 100 to <300 and ≥300 mg/g, respectively. Increasing UACR and decreasing eGFR were linked with higher risks of the primary outcome, heart failure hospitalization, a composite renal outcome and death (P-values for the Cochran-Armitage test for trends were all <.0001). Across UACR and eGFR subgroups, risks of cardiorenal events and death were generally lower or similar with liraglutide versus placebo. Conclusions: In a contemporary type 2 diabetes population, increasing baseline UACR and declining eGFR were linked with higher risks of cardiorenal events and death.

Published
2020

133. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

Author

Persson, Frederik, primary, Bain, Stephen C, primary, Mosenzon, Ofri, primary, Heerspink, Hiddo J.L., primary, Mann, Johannes F. E., primary, Pratley, Richard, primary, Raz, Itamar, primary, Idorn, Thomas, primary, Rasmussen, Søren, primary, Scholten, Bernt Johan von, primary, Rossing, Peter, primary, and Investigators, the LEADER Trial, primary

Published
2021
Full Text
View/download PDF

134. The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

Author

McEwan, Phil, primary, Morgan, Angharad R., additional, Boyce, Rebecca, additional, Bergenheim, Klas, additional, Gause‐Nilsson, Ingrid A.M., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, Johansson, Peter A., additional, Mosenzon, Ofri, additional, Cahn, Avivit, additional, and Wilding, John P.H., additional

Published
2021
Full Text
View/download PDF

135. Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents

Author

Tsur, Avishai M, primary, Hershkovich, Shir, additional, Zucker, Inbar, additional, Lutski, Miri, additional, Pinhas-Hamiel, Orit, additional, Vivante, Asaf, additional, Fischman, Maya, additional, Amir, Ofer, additional, Rotchild, Jacob, additional, Gerstein, Hertzel C, additional, Cukierman-Yaffe, Tali, additional, Friedensohn, Limor, additional, Mosenzon, Ofri, additional, Derazne, Estela, additional, Tzur, Dorit, additional, Tirosh, Amir, additional, Afek, Arnon, additional, Raz, Itamar, additional, and Twig, Gilad, additional

Published
2021
Full Text
View/download PDF

136. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

Author

Zelniker, Thomas A., primary, Morrow, David A., additional, Mosenzon, Ofri, additional, Goodrich, Erica L., additional, Jarolim, Petr, additional, Murphy, Sabina A., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John, additional, Bode, Christoph, additional, Lewis, Basil S., additional, Gause‐Nilsson, Ingrid, additional, Langkilde, Anna Maria, additional, Fredriksson, Martin, additional, Raz, Itamar, additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2020
Full Text
View/download PDF

138. Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents

Author

Fishman, Boris, primary, Grossman, Ehud, additional, Zucker, Inbar, additional, Orr, Omri, additional, Lutski, Miri, additional, Bardugo, Aya, additional, Bendor, Cole D., additional, Leiba, Yoav, additional, Cukierman-Yaffe, Tali, additional, Derazne, Estela, additional, Mosenzon, Ofri, additional, Tzur, Dorit, additional, Beer, Zivan, additional, Pinhas-Hamiel, Orit, additional, Fishman, Tamar, additional, Afek, Arnon, additional, Tirosh, Amir, additional, Raz, Itamar, additional, Gerstein, Hertzel C., additional, and Twig, Gilad, additional

Published
2020
Full Text
View/download PDF

142. Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study.

Author

Peled, Alon, Raz, Itamar, Zucker, Inbar, Derazne, Estela, Megreli, Jacob, Pinhas-Hamiel, Orit, Einan-Lifshitz, Adi, Morad, Yair, Pras, Eran, Lutski, Miri, Cukierman-Yaffe, Tali, Mosenzon, Ofri, Tzur, Dorit, Tirosh, Amir, Gerstein, Hertzel C., Afek, Arnon, and Twig, Gilad

Subjects
TYPE 2 diabetes, MYOPIA, INSULIN resistance
Abstract

Context: A correlation between myopia and insulin resistance has been suggested. Objective: We investigated the association between myopia in adolescence and type 2 diabetes (T2D) incidence in young adulthood. Methods: This population-based, retrospective, cohort study comprised 1 329 705 adolescents (579 543 women, 43.6%) aged 16 to 19 years, who were medically examined before mandatory military service during 1993 to 2012, and whose data were linked to the Israel National Diabetes Registry. Myopia was defined based on right-eye refractive data. Cox proportional models were applied, separately for women and men, to estimate hazard ratios (HRs) for T2D incidence per person-years of follow-up. Results: There was an interaction between myopia and sex with T2D (P < .001). For women, T2D incidence rates (per 100 000 person-years) were 16.6, 19.2, and 25.1 for those without myopia, and with mild-to-moderate and high myopia, respectively. These corresponded to HRs of 1.29 (95% CI, 1.14-1.45) and 1.63 (1.21-2.18) for women with mildto- moderate and high myopia, respectively, compared to those without myopia, after adjustment for age at study entry, birth year, adolescent body mass index, cognitive performance, socioeconomic status, and immigration status. Results persisted in extensive sensitivity and subgroup analyses. When managed as a continuous variable, every 1-diopter lower spherical equivalent yielded a 6.5% higher adjusted HR for T2D incidence (P = .003). There was no significant association among men. Conclusion: For women, myopia in adolescence was associated with a significantly increased risk for incident T2D in young adulthood, in a severity-dependent manner. This finding may support the role of insulin resistance in myopia pathogenesis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

143. Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood

Author

Bardugo, Aya, primary, Bendor, Cole D, additional, Zucker, Inbar, additional, Lutski, Miri, additional, Cukierman-Yaffe, Tali, additional, Derazne, Estela, additional, Mosenzon, Ofri, additional, Tzur, Dorit, additional, Beer, Zivan, additional, Pinhas-Hamiel, Orit, additional, Ben-Ami, Michal, additional, Fishman, Boris, additional, Ben-Ami Shor, Dana, additional, Raz, Itamar, additional, Afek, Arnon, additional, Gerstein, Hertzel C, additional, Häring, Hans-Ulrich, additional, Tirosh, Amir, additional, Levi, Zohar, additional, and Twig, Gilad, additional

Published
2020
Full Text
View/download PDF

144. Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58

Author

Cahn, Avivit, primary, Wiviott, Stephen D., additional, Mosenzon, Ofri, additional, Murphy, Sabina A., additional, Goodrich, Erica L., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Wilding, John P. H., additional, Leiter, Lawrence A., additional, Bhatt, Deepak L., additional, McGuire, Darren K., additional, Litwak, Leon, additional, Kooy, Adriaan, additional, Gause‐Nilsson, Ingrid A. M., additional, Fredriksson, Martin, additional, Langkilde, Anna Maria, additional, Sabatine, Marc S., additional, and Raz, Itamar, additional

Published
2020
Full Text
View/download PDF

147. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel

Author

Consoli, Agostino, primary, Czupryniak, Leszek, additional, Duarte, Rui, additional, Jermendy, György, additional, Kautzky‐Willer, Alexandra, additional, Mathieu, Chantal, additional, Melo, Miguel, additional, Mosenzon, Ofri, additional, Nobels, Frank, additional, Papanas, Nikolaos, additional, Roman, Gabriela, additional, Schnell, Oliver, additional, Sotiropoulos, Alexis, additional, Stehouwer, Coen D. A., additional, Tack, Cees J., additional, Woo, Vincent, additional, Fadini, Gian Paolo, additional, and Raz, Itamar, additional

Published
2020
Full Text
View/download PDF

150. 278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes

Author

VON HERRATH, MATTHIAS G., primary, BAIN, STEPHEN C., additional, BODE, BRUCE W., additional, CLAUSEN, JESPER OLE, additional, COPPIETERS, KEN, additional, GAYSINA, LEYLYA, additional, GUMPRECHT, JANUSZ, additional, HANSEN, TROELS K., additional, MATHIEU, CHANTAL, additional, PORTILLO, CRISTOBAL MORALES, additional, MOSENZON, OFRI, additional, SEGEL, STINE, additional, TSOUKAS, GEORGE M., additional, and PIEBER, THOMAS, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results